Correcting press release issued under same heading: Date in body text corrected to "November 6, 2025" as in headline. COPENHAGEN, Denmark, October 31, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2025 financial results on Thursday November 6, 2025, before opening of the Nasdaq CM. Evaxion’s Executive Management will host a conference call and webcast the ...

COPENHAGEN, Denmark, October 31, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2025 financial results on Friday October 31, 2025, before opening of the Nasdaq CM. Evaxion’s Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open ...

Gross proceeds from sales of shares amounting to $4.5 million and exercise of warrants providing a further $2.7 millionTotal gross inflow of cash of $14.7 million since the end of the second quarter 2025Evaxion now has cash on hand to fund its operations and R&D programs into the second half of 2027The exercises have reduced the number of outstanding warrants to purchase Evaxion American Depositary Shares (ADSs) by 1.0 million COPENHAGEN, Denmark, October 30, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a ...

Dr Tayton-Martin brings broad experience of biotech company building, fund-raising, M&A, business development and operations with a strong track record of strategic partnership dealsHer more than 30 years of experience include leadership roles in the UK and US, from early research through to product approval in cancer immunotherapy, making her the ideal candidate to lead the next stage of execution of Evaxion’s strategy Birgitte Rønø, who has served as interim Chief Executive Officer, will continue in her r ...

公司股价与评级 - Lake Street分析师Thomas Flaten将公司目标价从6美元上调至11美元 并维持买入评级 [1] - 公司股票被认为具有巨大上涨潜力的热门股 [1] 核心产品与临床进展 - 公司公布其个性化癌症疫苗EVX-01在晚期黑色素瘤中的两年期二期数据 [1] - EVX-01是一种基于个性化肽的癌症疫苗 用于一线治疗多种晚期实体癌 是公司的主要临床资产 [2] 平台验证与合作伙伴关系 - EVX-01的两年期数据以及默克公司对EVX-B3的选择权行使 进一步验证了公司的技术平台 [2] - 公司是一家临床阶段生物技术公司 开发人工智能驱动的免疫学疫苗 于2025年5月由Evaxion Biotech更名为Evaxion [3]

PresentationBenjamin Wolthers Welcome to this webinar sharing the 2-year readout from our Evaxion Phase II study in advanced melanoma. We are very, very happy with the virtual turnout for this call here. And together with the Professor Adnan Khattak, I look forward to sharing results and discussing data and implications of these data with all of you right from this important Phase II study in high-risk melanoma. So if we look into the next hour or so, we will be covering an exciting agenda. Initially, I wi ...

涉及的行业或公司 * 涉及的行业为生物技术/制药行业，专注于肿瘤免疫治疗领域 [1] * 涉及的公司为Evaxion Biotech A/S (纳斯达克代码: EVAX)，一家总部位于丹麦哥本哈根的生物技术公司 [3] * 核心候选药物为EVX-01，一种针对晚期黑色素瘤的个性化抗癌疫苗 [4] 核心观点和论据 **AI-Immunology平台与技术** * 公司的核心是专有的AI-Immunology平台，用于疫苗发现、设计和开发 [3] * 该平台整合基因组、转录组和蛋白质组数据，以识别最佳疫苗靶点 [3] * 平台在靶点选择方面显示出非常高的成功率，能诱导有效的疫苗特异性T细胞反应 [4] * 在二期试验中，AI平台识别的新抗原在81%的病例中诱导了T细胞反应，相比一期试验的约65%有所提高 [31] **EVX-01二期临床试验设计与结果** * 试验设计：纳入17名患者（16名可评估），为不可切除的III期或IV期黑色素瘤患者，治疗初治，ECOG状态0-1 [18][23] * 治疗方案：患者先接受标准pembrolizumab（Keytruda）单药治疗12周，随后在第12周开始加用EVX-01个性化疫苗（6次初始剂量+4次加强剂量） [21][22] * 安全性：EVX-01与pembrolizumab联合治疗耐受性良好，安全性良好，与一期数据一致 [24][25][36] * 绝大多数不良事件为1级或2级（如疲劳、注射部位反应、身体疼痛），仅有一例3/4级不良事件（胰腺炎）被认为与pembrolizumab相关，而非疫苗 [25] * 疗效：在12周pembrolizumab单药治疗后，客观缓解率（ORR）为50% [26] * 加用EVX-01疫苗后，最佳客观缓解率（ORR）达到75%（12/16名患者） [26][30] * 转化率（加深缓解）为54%（7/13名患者），包括3名患者从部分缓解转化为完全缓解，4名患者从疾病稳定转化为部分缓解 [29][30] * 中位随访约两年时，中位无进展生存期和总生存期尚未达到，92%的应答者在24个月时仍保持持续应答 [30][37] * 疫苗制造成功率为100%，所有入组患者均成功制造出疫苗 [38] **加强剂量的重要性** * 与一期试验（无加强剂量）相比，二期试验加入了加强剂量（第30、42、54、78周） [8][21] * 数据显示加强剂量能进一步改善并维持疫苗特异性T细胞反应，强调了其重要性 [22][32][33] * 由于初步疗效和加强剂量的益处，已开放扩展阶段以增加两次加强剂量 [22] **行业背景与竞争格局** * 晚期黑色素瘤治疗自2011年免疫疗法出现后取得显著进展，当前标准治疗（如ipilimumab + nivolumab组合）的应答率约50-60%，但3级及以上不良事件发生率高达50-60% [15][16][42] * 存在对更有效、更安全、更个性化治疗方案的需求，以帮助另外50%对现有疗法无效的患者 [17] * 其他个性化癌症疫苗（如mRNA疫苗）也在开发中，但EVX-01是首个在试验中纳入并证明加强剂量有效性的方案 [44][61] * 抗体药物偶联物和双特异性抗体等其他疗法在黑色素瘤领域尚未有明确作用，但正处于探索阶段 [55][56] 其他重要内容 **未来发展与合作潜力** * 公司正在与相关合作伙伴就EVX-01的进一步开发进行讨论 [39][40][73] * 正在与全球监管机构进行持续讨论，以规划下一步发展 [73][74] * EVX-01的制造过程（测序、AI预测、肽疫苗生产）被认为相对直接，可能便于未来的合作与扩展 [40] * 未来可能探索的治疗场景包括：联合治疗用于早期治疗线、挽救对前期治疗无应答的患者、以及在新辅助/辅助治疗 setting 中的应用 [66][68][69] **试验局限性** * 当前二期试验规模较小（n=16），需要更大规模的随机试验来获得更具统计学意义的结论 [36][47][77] * 由于患者数量少，无法基于BRAF或PD-L1状态等生物标志物得出有意义的亚组分析结论 [74]

75% Objective Response Rate as 12 out of 16 advanced melanoma patients had objective clinical responses, with 11 of the 12 responders continuing to respond at 24 months follow-upImmune activation observed in all patients with 81% of EVX-01’s vaccine targets triggering a specific responseTreatment was well toleratedData is presented today at the ESMO Congress and will be discussed at a webinar with key opinion leader Professor Muhammad Adnan Khattak on October 22, 2025 COPENHAGEN, Denmark, October 17, 2025 - ...

Evaxion Biotech A/S (EVAX) 投资前景 - 公司目标价格为-0.34美元，较其7.84美元的市场价格低104.29%，显示出分析师对其前景的悲观看法 [1][3] - 目标价与市场价之间的巨大差距反映了市场对其未来业绩和达成目标能力的担忧 [3][5] TransCode Therapeutics, Inc. (RNAZ) 投资前景 - 公司当前股价为14.28美元，目标价格为16.21美元，表明存在13.52%的增长潜力 [2][4] - 积极的目标价格变化表明分析师对其增长前景充满信心，使其成为生物技术领域更具吸引力的投资机会 [2][4][5] 生物技术行业分析师观点对比 - EVAX与RNAZ目标价格的鲜明对比凸显了分析师对生物技术领域内不同公司信心和投资吸引力的显著差异 [5]

C O R P O R A T E P R E S E N T A T I O N – O C T O B E R 2 0 2 5 DE C ODI N G T HE H UM A N I M MUN E SY ST EM T O DE VEL OP NO VEL V A CC I N ES FOR C A NC E R A N D I N FEC T I OUS DI SEA SE S WI T H OUR A I - I MM UN OL OGY P LA T FO RM EVAX EVAX A black and Forward-looking statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words "target," "bel ...